CompletedPHASE1, PHASE2NCT01621256

Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss

Studying Sudden sensorineural hearing loss

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nordmark Arzneimittel GmbH & Co. KG
Principal Investigator
Martin Canis, MD PhD
Department for Otorhinolaryngology, LM University Munich
Intervention
Ancrod(drug)
Enrollment
31 target
Eligibility
18-70 years · All sexes
Timeline
20132018

Study locations (7)

Collaborators

ClinSupport GmbH · MWI Medizinisches Wirtschaftsinstitut GmbH · ProjectPharm s.r.o. · LCR Leading Clinical Research s.r.o. · X-act Cologne Clinical Research GmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01621256 on ClinicalTrials.gov

Other trials for Sudden sensorineural hearing loss

Additional recruiting or active studies for the same condition.

See all trials for Sudden sensorineural hearing loss

← Back to all trials